Supplemental Digital Content is available in the text.
Keywords: blood–brain barrier, intracerebral hemorrhage, memantine, neuronal nitric oxide synthase, peroxynitrite
Abstract
Memantine has demonstrated beneficial effects on several types of brain insults via therapeutic mechanisms mainly related to its activity as a receptor antagonist of N-methyl-d-aspartate. However, the influences of memantine on intracerebral hemorrhage (ICH) remain obscure. This research probed into the neurovascular protective mechanisms of memantine after ICH and its impacts on neuronal nitric oxide synthase (nNOS) ser1412 phosphorylation. ICH model was established by employing intrastriatal collagenase injection in rats. After modeling, rats were then allocated randomly into sham-operated (sham), vehicle-treated (ICH+V), and memantine-administrated (ICH+M) groups. Memantine (20 mg/kg/day) was intraperitoneally administered 30 min after ICH and thenceforth once daily. Rats were dedicated at 0.25, 6, 12, 24 h, 3 and 7 d post-ICH for measurement of corresponding indexes. Behavioral changes, brain edema, levels of nNOS ser1412 phosphorylation, peroxynitrite, matrix metalloproteinase (MMP)-9, NLRP3, IL-1β and numbers of dying neurons, as well as the cellular localization of gelatinolytic activity, were detected among the groups. Memantine improved the neurologic deficits and mitigated brain water content, levels of MMP-9, NLRP3, IL-1β and dying neurons. Additionally, treatment with memantine also reduced nNOS ser1412 phosphorylation and peroxynitrite formation compared with the ICH+V group at 24 h after ICH. In situ zymography simultaneously revealed that gelatinase activity was primarily colocalized with vessel walls and neurons. We concluded that memantine ameliorated blood–brain barrier disruption and neurologic dysfunction in an ICH rat model. The underlying mechanism might involve repression of nNOS ser1412 phosphorylation, as well as peroxynitrite-related MMP-9 and NLRP3 inflammasome activation.
Introduction
Intracerebral hemorrhage (ICH) is the most menacing subtype of stroke and has an extremely poor prognosis. Nearly one-third of ICH patients die within 1 month following ICH and a large proportion of survivors remain disabled [1,2]. ICH is accompanied by the production of abundant free radicals (e.g., reactive oxygen species and reactive nitrogen species, namely ROS and RNS), which lead to blood–brain barrier (BBB) disruption, resulting in secondary edema in the brain and poor neurological deficits [3]. Besides, ICH-related free radicals also trigger inflammatory cascade involved with the progression of secondary brain edema [4]. Notedly, the structure of the BBB unit is composed of a basement membrane, endothelial cells, matrix, astrocytes and neurons, and disruption of BBB integrity is directly bound up with the aggravation of brain edema and neurologic defects [5]. However, which free radicals have the most destructive action on neurovascular units, and their specific molecular mechanism is still unclear.
Peroxynitrite (ONOO−), which is formed by the reaction of nitric oxide and superoxide in a diffusion-limited way [6]. Excessive accumulation of ONOO− can cause a serious effect on the BBB integrity in various central nervous system (CNS) disorders, including ICH, bringing about an adverse prognosis [3,7]. Peroxynitrite can compromise the integrity of the BBB by suppressing the energy metabolism of the cell, attenuating the activity of Na+/K+-ATPase, and activating matrix metalloproteinases (MMPs) [6–9]. Importantly, recent researches reported that ONOO− implicates activation of NLRP3 (NOD-like receptor family, pyrin domain containing 3) inflammasome, which mediates the inflammatory cascade and secondary brain insults post-ICH [4].
Preceding studies have investigated that the excessive release of glutamate associated with neuronal cell damage in several CNS pathologies [10,11], concurrently revealing that accompanied pathophysiological processes mediate more glutamate formation correlated to the stimulation of N-methyl-d-aspartate receptors (NMDARs) [12,13]. It has been experimentally validated that nitric oxide was involved in mediating NMDA neurotoxicity [14]. Furthermore, three neuronal nitric oxide synthase (NOS) isoforms including endothelial NOS, neuronal NOS, and inducible NOS are known to produce nitric oxide, and potent evidence hints that a particular causality exists between nNOS and NMDARs which closely related to glutamate excitotoxicity and subsequent neural damage [15,16].
Large amounts of glutamate is released during the pathophysiology of distinct CNS disorders, leading to NMDAR stimulation [17]. Memantine, the NMDAR antagonist, has recently demonstrated a powerful brain-protective effect in the treatment of disparate CNS diseases such as cerebral ischemia [18,19], infantile rat hydrocephalus [20], traumatic brain injury [21,22] and subarachnoid hemorrhage [16,23]. Overactivation of the complex of NMDAR, postsynaptic density protein 95 and nNOS produces large amounts of nitric oxide and superoxide anions (O2−), ultimately leading to the result of peroxynitrite formation [3,24]. More specifically, potent evidence indicated that nNOS phosphorylation at the site of Ser1412 was responsible for the sustained peroxynitrite formation and the resultant neuronal loss [25].
Although above-mentioned evidences have depicted the protective function of memantine treatment in various CNS diseases, its impacts on nNOS and peroxynitrite as well as involved downstream targets after ICH remain unclear. The current study aimed to further clarify the treatment action of memantine on brain injury in ICH rats and determined probably involvement of the nNOS phosphorylation and peroxynitrite-related signaling pathway.
Methods
Animals
A total of 98 adult male Sprague-Dawley (SD) rats (6 rats died after surgery were eliminated) weighing between 250 and 300 g were purchased and utilized for our study. All the experimental procedures and protocols of the present study were authorized by the Ethics Committee of Nanchang University in conformity to the guidelines for the Care and Use of Laboratory Animals by the National Institutes of Health.
Experimental groups, drugs and dose
Rats were randomly allocated to two separate experiments as described in Supplementary Figure 1, Supplement digital content 1, http://links.lww.com/WNR/A611. The experimental grouping information was blinded to the researchers and performers who conducted the behavioral scores and gelatinolytic activity tests as well as data analysis. Experiment 1 (Supplementary Figure 1, Supplement digital content 1, http://links.lww.com/WNR/A611) was set to study the time course of nNOS ser1412 and 3-nitrotyrosine (3-NT, a recognized hallmark of ONOO− production) in the ipsilateral brain tissues. Experiment 2 (Supplementary Figure 1, Supplement digital content 1, http://links.lww.com/WNR/A611) was established to probe into the effects of memantine on BBB integrity, brain edema and neurological deficits as well as related pathomechanism. Rats were randomly divided into three groups (1) sham group (surgery without ICH induction, n = 18), (2) ICH+vehicle (ICH+V, n = 18) group (saline treatment) and (3) ICH+ memantine group (ICH+M, n = 18) group (memantine treatment). Rats in the ICH+M group received intraperitoneal memantine (Sigma-Aldrich, USA, St. Louis, Missouri, 20 mg/kg/day, prepared in freshly sterile saline) 30 min after the ICH induction in rats, then injected once daily until the rats were killed. The specific dose of memantine decided in our study was based on the previously published studies [26,27]. It is reported that 20 mg/kg memantine (intraperitoneal) can not only achieve effective brain concentration but also significantly attenuate brain inflammation and apoptosis, thus playing a neuroprotective role. An equivalent volume of saline instead of memantine was administrated in the ICH+V group.
Intracerebral hemorrhage rat model
Male SD rats were anesthetized by intraperitoneal injection of pentobarbital sodium (45 mg/kg) and then fasten to a stereotaxic frame, just as mentioned before [4]. The heating pad was selected to maintain the animals’ temperature at 36.5–37.3°C. A microsyringe needle inserted into the striatum after a burr hole was made by the stereotactic coordinates of 0.2 mm anterior, 2.8 mm lateral and 5.8 mm ventral to the bregma. ICH was induced by microinjection of 2 μL sterile saline containing 0.5 IU collagenase (Sigma-Aldrich) for more than 5 min. Then the burr hole was sealed, and the rats recovered under a comfortable environment with unstinted access to food and water.
Behavioral testing
Behavioral testing was conducted by two investigators blinded to the groups at 24 and 72 h after ICH by using the modified neurological severity score (mNSS) [28]. The range of grades from 0 to 18 includes the tests of movement, sensation, reflexes and balance. The mNSS from 1 to 6 demonstrated mild injury, from 13 to 18 demonstrated severe injury and from 7 to 12 indicated the severity of injury in between.
Blood–brain barrier integrity detection
BBB permeability was analyzed according to the foregoing research with small modifications [29]. The 5% Evan’s blue solution was injected via tail vein to rats at 22 h after ICH. Cardiac perfusion was followed at 2 h after Evan’s blue administration to eliminate the residual Evan’s blue in the cerebral circulation. After the brain removed, a certain amount of N,N-dimethylformamide (DMF) was employed to isolate the hemispheres. The mixture liquid obtained followed by mechanically homogenized was kept in virtual darkness for 72 h at room temperature. The suspension was centrifuged for 30 min and Evan’s blue content in the supernatant of tissue homogenates was spectrofluorimetrically analyzed. Leaky Evan’s blue was demonstrated as micrograms per gram brain weight.
Immunofluorescence
After anesthetized with pentobarbital sodium, the rats were perfused with PBS buffer solution and 4% paraformaldehyde transcardially, as described previously [30,31]. Once removed, the brains were successively postfixed, embedded and cut into slices. After deparaffinized, sections were microwaved in citrate buffer for antigen retrieval and incubated overnight at 4°C with the following primary antibodies: mouse monoclonal anti-3-NT antibody (Abcam, Cambridge, Massachusetts), rabbit polyclonal anti-MMP-9 antibody (Santa Cruz, California, USA), and rabbit polyclonal anti-CD68 (Abcam). After incubation with fluorescent conjugated secondary antibodies (Alexa Fluor 594 goat anti-mouse IgG, 1:500, Abcam; Alexa Fluor 488 goat anti-rabbit IgG, 1:500, Abcam) under room temperature for 1 h, the sections were restained by Hoechst 33258 for 10 min. The images were obtained by fluorescent microscopy (Bx51; Olympus Corporation, Shinjuku-ku, Japan).
In situ zymography testing
The commercial kit was used to detect gelatinase MMP-9 in situ zymography as previously described (Shanghai, China) [30]. Fresh frozen sections with 10 µm thickness were incubated with gelatin conjugate at 4°C for 10 min and carried on for 1 h at 37°C. For double-staining, the tissue slices were incubated with primary antibodies for the labeling of neurons (NeuN, Abcam) and vessel basal lamina (fibronectin, Abcam) overnight at 4°C after the gelatinolytic activity of various groups was quantified. Investigators were blinded to the experimental groups. The images were taken by the confocal microscope (OLYMPUS).
Western blot analysis
The extraction of tissue protein in ipsilateral hemispheres tissues was performed following the instructions of the reagents kit and using RIPA buffer. The concentrations of protein were detected by the BCA Protein Assay Kit (Sigma-Aldrich). After divorced by the SDS-PAGE, the protein samples were transferred to a PVDF filter membrane. Following being blocked with 5% nonfat milk, primary antibodies (anti-phosphorylated nNOS at Ser1214, Sigma-Aldrich; anti-3-nitrotyrosine, Abcam; anti-matrix metalloproteinase-9 (MMP-9), Abcam; ZO-1, Invitrogen, USA; NLRP3, Abcam; IL-1β, Abcam) were incubated respectively and followed by incubation with species-specific secondary antibodies (goat anti-mouse IgG 1:2000, Santa Cruz Biotechnology; goat anti-rabbit IgG 1:2000, Santa Cruz Biotechnology). Densitometry analysis was performed with Image J software after normalization to GAPDH.
Statistical analysis
All data were shown as mean ± SD. Statistical analysis was performed using SPSS 20.0 software (SPSS, Chicago, Illinois, USA). Comparison among groups was determined via one-way analysis of variance and followed by the LSD or Dunnett’s T3 test for the two groups’ comparison within the multiple groups. Differences were considered to be statistically significant at P < 0.05.
Result
Treatment with memantine inhibits the neuronal death and ameliorates the behavioral function of rats after intracerebral hemorrhage
Fluoro–Jade staining method was applied to detect the dying neurons after ICH. As shown in Fig. 1a, b, the number of FJC+ neurons was evidently increased at 24 h after ICH as compared with the sham group (P < 0.05). Administration of memantine notedly reduced neuronal death compared with the vehicle group (P < 0.01). Next, we adopted the mNSS tests to evaluate the neurological function (Fig. 1c). The mNSS scores were significantly increased at 24 and 72 h after ICH attack as compared with the sham group (P < 0.01). In contrast, memantine treatment evidently ameliorated the neurological deficits at the above time points (P < 0.05).
Fig. 1.
Effect of memantine on the number of FJC+ neurons and neurological function scores. Degenerated neurons (a), quantitative analysis (b) and neurological scores (c). Fluoro–Jade staining demonstrated that administration of memantine markedly decreased neuron death compared with the vehicle group at 24 h post-ICH. Similarly, significantly lowered mNSS scores at 24 and 72 h of ICH rats with the treatment of memantine. n = 6 in each group. Data are presented as the mean ± SD. #P < 0.05, *P < 0.01, scale bar = 50 µm. ICH, intracerebral hemorrhage; mNSS, modified neurological severity score.
Time course expression levels of neuronal nitric oxide synthase ser1412 and 3-nitrotyrosine after intracerebral hemorrhage
The expression levels of phosphorylated nNOS and 3-NT in the rat brain at designated time points (sham, 0.25, 6, 12, 24 h, 3 and 7 d post-ICH) were detected by western blot (Fig. 2a, b). nNOS ser1412 level sharply increased as early as 6 h after ICH and showed a relative reduction at 12 h, peaked at 24 h and then diminished gradually. Despite falling evidently at 7 days, it was still higher than the sham group. Significant differences exist between ICH groups and sham groups at the above time points (P < 0.05). In contrast to nNOS ser1412, 3-NT level in the injured brain tissues also started to markedly increase as early as 6 h post-ICH, peaked at 24 h and then diminished slowly. Similar to nNOS ser1412, it was still higher than the sham group at 7 days. The differences were statistically significant at the indicated time points (P < 0.01).
Fig. 2.
The expression of nNOS ser1412 and 3-NT at different time points after ICH. (a) Western blot analysis and (b, c) densitometry. Western blot analysis of nNOS ser1412 and ONOO− revealed that the expression trend of nNOS ser1412 or 3-NT after ICH was basically consistent, and both of them reached the maximum at 24 h after ICH (n = 4). The molecular weight of nNOS ser1412 and 3-NT was approximately 170 and 72 kDa, respectively. #P< 0.05, *P < 0.01. ICH, intracerebral hemorrhage; nNOS, nitric oxide synthase; 3-NT, 3-nitrotyrosine.
Memantine decreased the phosphorylation of neuronal nitric oxide synthase at ser1412 and inhibited peroxynitrite formation following intracerebral hemorrhage
Phosphorylation of nNOS at ser1412 is closely associated with nitric oxide production attributed to the increased nNOS activity, resulting in disruption of the BBB [32]. We determined if memantine inhibited nNOS ser1412 phosphorylation, nNOS activity and subsequent pathway. By western blot (Fig. 3a, b, c), the levels of phosphorylated ser1412 and peroxynitrite were remarkably elevated at 24 h after ICH. Whereas memantine administration effectively decreased the levels of NOS ser1412 phosphorylation and peroxynitrite. By immunofluorescence, we also found that memantine treatment markedly reduced the expression of peroxynitrite compared with the ICH+V group at 24 h post-ICH (Fig. 3d). Fluorescent double-labeling indicated that the formation of 3-NT was mainly localized in CD68 positive microglia/macrophages (Fig. 3e) (P < 0.01).
Fig. 3.
Treatment with memantine decreased the levels of nNOS Ser1412 and 3-NT. (a)Western blot analysis. (b, c) Relative densities have been normalized against the sham group. (d) Immunofluorescence analysis. The vehicle group had an evident higher level of nNOS ser1412 phosphorylation and 3-NT than the sham-operated group. Memantine treatment suppressed the elevation of nNOS ser1412 phosphorylation and 3-NT when compared to the vehicle group at 24 h post-ICH. The molecular weight of nNOS ser1412 and 3-NT was approximately 170 and 72 kDa, separately. (e) Double labeling of 3-NT and CD-68 showed that the formation of 3-NT is mainly localized in CD68 positive cells. n = 6 in each group. Data are presented as the mean ± SD. #P < 0.05, *P < 0.01, scale bar = 50 µm. ICH, intracerebral hemorrhage; nNOS, nitric oxide synthase; 3-NT, 3-nitrotyrosine.
Cellular localization of gelatinolytic activity following intracerebral hemorrhage
As shown by gelatin in situ zymography, colocalization of gelatinolytic activity and cell markers revealed that MMP-9 enzymatic activity was primarily observed in FN+ vessel walls and NeuN+ neurons (Fig. 4a, b). These tests showed that gelatinolytic activity could be activated in a wide range of cell types, including vessel walls and neurons, with consequently detrimental effects following ICH.
Fig. 4.
Cellular localization of MMP-9 activity and effect of memantine on MMP-9 activity and protein expression following ICH. The result of colocalization indicated that MMP-9 enzymatic activity was primarily detected in FN+ vessel walls (a) and NeuN+ neurons (b) following ICH. Original magnification, ×600. In situ zymography and quantitative analysis (c, e, n = 6), western blot and densitometric analysis (d, f, n = 4). Administration with memantine remarkably attenuated MMP-9 expression and gelatinolytic-positive cell numbers compared with the vehicle-treated group at 24 h after ICH (P < 0.01). The molecular weight of MMP-9 was approximately 89 kDa. Data are presented as the mean ± SD. #P < 0.05, *P < 0.01, scale bar = 50 µm. ICH, intracerebral hemorrhage; MMP, matrix metalloproteinases.
Treatment with memantine downregulated the increased MMP-9 activity and protein expression
MMP-9 played an important role in maintaining BBB integrity and we, therefore, investigated MMP-9 levels using in situ zymography(Fig. 4c, e) and western blot (Fig. 6d, f). The gelatinolytic activity and protein expression of MMP-9 was dramatically increased at 24 h after ICH. Whereas treatment with memantine markedly attenuated the MMP-9 protein levels and quantities of gelatinolytic-positive cells and vessels when compared with the vehicle-treated group (P < 0.01).
Fig. 6.
Effect of memantine injection on the protein levels of NLRP3 and IL-1β. Western blot (a) and densitometric analysis (b, c, n = 4). Injection with memantine remarkably suppressed the increases of NLRP3 and IL-1β compared with the vehicle-treated group at 24 h after ICH. The molecular weight of NLRP3 and IL-1β was approximately 120 and 17 kDa, separately. Data are presented as the mean ± SD. #P< 0.05, *P< 0.01. ICH, intracerebral hemorrhage.
Administration with memantine attenuated the destruction of tight junction protein zonula occludens-1 and ameliorated the blood–brain barrier permeability
The integrity of the BBB requires the support of tight junction proteins [e.g., zonula occludens-1 (ZO-1)]. Thus, using western blot (Fig. 5a, b), we investigated whether memantine protects BBB via the modulation of ZO-1. The ZO-1 was evidently reduced at 24 h after ICH attack compared with the sham group. Contrarily, administration with memantine notably counteracted the ICH-mediated decreasing expression of ZO-1 compared to the ICH+V group (P < 0.05). Furtherly, we compared the exosmotic Evan’s blue intensity between the memantine and the vehicle group. At 24 h post-ICH, memantine administration markedly attenuated BBB leakage and ameliorated the BBB permeability when compared with the vehicle group (Fig. 5c) (P < 0.01).
Fig. 5.
Influence of memantine on the expression of zonula occludens-1 (ZO-1) and BBB permeability. Western blot (a) and quantitation (b, n = 4) as well as Evan’s blue measurement (c, n = 6). Memantine treatment significantly increased the expression of ZO-1 and attenuated the leakage of Evan’s blue in the damaged brain tissues of rats compared with the vehicle group. Bands for ZO-1 migrated at approximately 220 kDa. Data are presented as mean ± SD. #P < 0.05, *P < 0.01. BBB, blood–brain barrier.
Treatment with memantine repressed the activation of NLRP3 and subsequent IL-1β production
The activation of NLRP3 inflammasome and the associated inflammatory cascade is bound up with the hemorrhagic brain injury. Current results demonstrated that at 24 h after ICH induction, the protein levels of NLRP3 and IL-1β were significantly enhanced, and memantine injection remarkably weakened the increases of NLRP3 and IL-1β (Fig. 6a, b, c, P < 0.05).
Discussion
Following ICH, the hematoma degradation products trigger inflammatory responses in the perihematomal region [33]. Activation of glial cells, including astrocytes and microglia, is followed by the initiation of inflammatory responses and induction of proinflammatory and neurotoxic mediators, leading to BBB disruption and subsequent brain edema, neural apoptosis and impaired neurologic outcomes [34–36]. We, therefore, attempted to characterize the actions of memantine on the neurologic impairment, apoptosis of cells, nNOS and peroxynitrite formation, BBB integrity and related mechanisms in ICH rats.
As the reaction between nitric oxide and superoxide anions (O2−) and consequent oxidative product, peroxynitrite has been reported to feature in a wide variety of biological processes related to cell damage, destruction of BBB integrity, endothelial dysfunction and neurodegeneration, and is consequently correlated with a poor prognosis [37–39].
Although relevant researches have confirmed that the upregulation of iNOS increased the production of nitric oxide, iNOS was not detectable until 1 day after ICH [40]. Accompany with elevated glutamate concentration in the early phase of ICH, nNOS was aberrantly activated and exerted a dominant role in the formation of nitric oxide and O2−, thereby resulting in the sustained production of peroxynitrite [30]. Given that peroxynitrite formation is closely relevant to glutamate concentration and BBB disruption, our study revealed that memantine salvaged the BBB disruption by suppressing nNOS activation and peroxynitrite formation as well as underlying pathogenic targets.
The nNOS has been implicated in the breakdown of BBB integrity in several diseases, including heat stress-induced brain injury [41], transient cerebral ischemia [42] and subarachnoid hemorrhage [16]. Regarding the role of peroxynitrite, we previously revealed that ONOO− may mediate the activation of MMP-9 by two principal mechanisms. Specifically, it may upregulate nuclear factor-κB (NF-κB) expression indirectly and eventually modify MMP-9 transcription or may affect pro-MMP-9 directly, leading to significantly increased release of MMP-9 [43,44]. The activation of transcriptional and translational pathways regulates the expression of MMP-9 via relevant element-binding sites of functional enhancer, including NF-κB and activator protein-1 [45–47]. Increasing evidence have shown that MMPs exert a biological role in CNS diseases, including ICH [48,49], and peroxynitrite-mediated activation of MMP-9 has been predominantly linked to tight junction proteins degradation, BBB disruption and tissue damage [50,51]. In the setting of ischemic [25] and hemorrhagic storke [32] model, enhanced phosphorylation of nNOS at Ser1412 was closely associated with the increased nNOS activity and subsequent nitric oxide production, which ultimately results in the excessive formation of ONOO−. Inhibition of nNOS phosphorylation at Ser1412 led to decreased levels of ONOO− [25]. In addition, it is reported that levels of phosphorylated Ser1412 were elevated as early as 1 h after cerebral ischemia-reperfusion [34,52,53]. In this context, we discovered that the nNOS exerted detrimental effects through nNOS ser1412 phosphorylation and nitric oxide overproduction as well as the resultant formation of ONOO−, which collaborated with MMP-9 and negatively contributed to BBB disruption and neuronal damage after ICH.
NLRP3 inflammasome, which was consisted of an NLRP3 scaffold, adaptor apoptosis speck-like protein (ASC) and the effector procaspase-1 [54], played a pivotal role in cerebrovascular diseases and have been reported to mediate BBB destruction and increased brain edema after cerebral ischemia [55,56]. More significantly, recent reports have shown that NLRP3 can be activated by reactive oxygen species (including peroxynitrite), Ca2+ signaling, and mitochondrial dysfunction [4]. Our results indicated that enhanced NLRP3 and IL-1β evidently decreased after memantine treatment, indicating that memantine can inhibit the inflammatory processes, which was in accord with the previous results [57,58]. Intriguingly, recent evidence demonstrated that the NLRP3-caspase-1 inflammasome directly activates MMP-9 by cleaving its N-terminal inhibitory domain. Genetic knockdown or inhibition of NLRP3 remarkably diminished the cleavage and activation of MMP-9 as well as mitigated the aortic destruction in a mice model of sporadic aortic aneurysm and dissection [59].
Memantine has been reported to exert an antagonistic effect on NMDARs, and to inhibit the Ca2+-dependent cascade and nNOS signaling during the pathologic activation of NMDARs [60]. Previous studies showed that memantine had neuroprotective effects against several diseases, including Alzheimer’s disease [61], hypoxia/ischemia [26], neuropathic pain [62] and Parkinsonism [26]. The relevant mechanisms are related to the attenuation of active caspase-3 levels and cell apoptosis, and the prevention of endothelial excitotoxicity, as well as the suppression of endogenous tPA upregulation. Notably, tissue plasminogen activator (tPA) is a selective activator of NMDA receptor-dependent signaling and neurotoxicity [63] and has been recognized as a promoter of MMP-9 activation and resultant hematoma expansion after ICH [57]. Surprisingly, memantine also exerted a powerful inhibitory action on the upregulation of tPA and ultimately reduced the MMP-9 level in the hemorrhagic brain [57]. The present research focused on the protective effect of memantine on BBB integrity within an ICH model, and revealed that it acted via a certain mechanism related to NMDAR antagonism, leading to the inhibition of nNOS ser1412 phosphorylation, decreased nNOS signaling and subsequently decreased production of peroxynitrite, MMP-9 and NLRP3.
Collectively, although other factors may also be implicated in the decreases of nNOS activation and peroxynitrite formation, the current results suggested that the inhibitory effect of memantine on nNOSser1412 phosphorylation and peroxynitrite-related MMP-9 and NLRP3 activation may, at least, in part help to prevent BBB disruption and neurological deficits in ICH rats.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (Nos. 81760224), Youth Science Foundation of Jiangxi Province (20171BAB215019), Science and technology research Foundation of Jiangxi Provincial department of education (GJJ160123), and Foundation of Jiangxi health and Family Planning Commission (20185081). This study was also supported by Nature Science Foundation of Hubei Province (No.2019CFC863).
Conflicts of interest
There are no conflicts of interest.
Supplementary Material
Footnotes
Xiaowei Chen and Xu Xiang contributed equally to the writing of this article.
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.neuroreport.com.
References
- 1.You S, Zheng D, Delcourt C, Sato S, Cao Y, Zhang S, et al. Determinants of early versus delayed neurological deterioration in intracerebral hemorrhage. Stroke. 2019; 50:1409–1414. [DOI] [PubMed] [Google Scholar]
- 2.Cordonnier C, Demchuk A, Ziai W, Anderson CS. Intracerebral haemorrhage: current approaches to acute management. Lancet. 2018; 392:1257–1268. [DOI] [PubMed] [Google Scholar]
- 3.Ding R, Feng L, He L, Chen Y, Wen P, Fu Z, et al. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats. Neuroscience. 2015; 297:182–193. [DOI] [PubMed] [Google Scholar]
- 4.Zeng J, Chen Y, Ding R, Feng L, Fu Z, Yang S, et al. Isoliquiritigenin alleviates early brain injury after experimental intracerebral hemorrhage via suppressing ROS- and/or NF-κB-mediated NLRP3 inflammasome activation by promoting Nrf2 antioxidant pathway. J Neuroinflammation. 2017; 14:119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010; 37:13–25. [DOI] [PubMed] [Google Scholar]
- 6.Qayyum I, Zubrow AB, Ashraf QM, Kubin J, Delivoria-Papadopoulos M, Mishra OP. Nitration as a mechanism of Na+, K+-ATPase modification during hypoxia in the cerebral cortex of the guinea pig fetus. Neurochem Res. 2001; 26:1163–1169. [DOI] [PubMed] [Google Scholar]
- 7.Chen H, Chen X, Luo Y, Shen J. Potential molecular targets of peroxynitrite in mediating blood-brain barrier damage and haemorrhagic transformation in acute ischaemic stroke with delayed tissue plasminogen activator treatment. Free Radic Res. 2018; 52:1220–1239. [DOI] [PubMed] [Google Scholar]
- 8.Suofu Y, Clark J, Broderick J, Wagner KR, Tomsick T, Sa Y, Lu A. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase activation and neurovascular injury after prolonged cerebral ischemia in rats. J Neurochem. 2010; 115:1266–1276. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cassina A, Radi R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys. 1996; 328:309–316. [DOI] [PubMed] [Google Scholar]
- 10.Hillered L, Vespa PM, Hovda DA. Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Neurotrauma. 2005; 22:3–41. [DOI] [PubMed] [Google Scholar]
- 11.Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium. 2003; 34:325–337. [DOI] [PubMed] [Google Scholar]
- 12.Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988; 1:623–634. [DOI] [PubMed] [Google Scholar]
- 13.Sarrafzadeh A, Haux D, Küchler I, Lanksch WR, Unterberg AW. Poor-grade aneurysmal subarachnoid hemorrhage: relationship of cerebral metabolism to outcome. J Neurosurg. 2004; 100:400–406. [DOI] [PubMed] [Google Scholar]
- 14.Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 1997; 20:132–139. [DOI] [PubMed] [Google Scholar]
- 15.Sehba FA, Chereshnev I, Maayani S, Friedrich V, Jr, Bederson JB. Nitric oxide synthase in acute alteration of nitric oxide levels after subarachnoid hemorrhage. Neurosurgery. 2004; 55:671–677. [DOI] [PubMed] [Google Scholar]
- 16.Huang CY, Wang LC, Wang HK, Pan CH, Cheng YY, Shan YS, et al. Memantine alleviates brain injury and neurobehavioral deficits after experimental subarachnoid hemorrhage. Mol Neurobiol. 2015; 51:1038–1052. [DOI] [PubMed] [Google Scholar]
- 17.Tanaka A, Ito Y, Kawasaki H, Kitabayashi C, Nishioka R, Yamazato M, et al. Effects of memantine on nitric oxide production and hydroxyl radical metabolism during cerebral ischemia and reperfusion in mice. J Stroke Cerebrovasc Dis. 2018; 27:1609–1615. [DOI] [PubMed] [Google Scholar]
- 18.Liu Y, Huang Y, Xu Y, Qu P, Wang M. Memantine protects against ischemia/reperfusion-induced brain endothelial permeability. IUBMB Life. 2018; 70:336–343. [DOI] [PubMed] [Google Scholar]
- 19.Gu SX, Sonkar VK, Katare PB, Kumar R, Kruger WD, Arning E, et al. Memantine protects from exacerbation of ischemic stroke and blood brain barrier disruption in mild but not severe hyperhomocysteinemia. J Am Heart Assoc. 2020; 9:e013368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Cabuk B, Etus V, Bozkurt SU, Sav A, Ceylan S. Neuroprotective effect of memantine on hippocampal neurons in infantile rat hydrocephalus. Turk Neurosurg. 2011; 21:352–358. [DOI] [PubMed] [Google Scholar]
- 21.Abrahamson EE, Poloyac SM, Dixon CE, Dekosky ST, Ikonomovic MD. Acute and chronic effects of single dose memantine after controlled cortical impact injury in adult rats. Restor Neurol Neurosci. 2019; 37:245–263. [DOI] [PubMed] [Google Scholar]
- 22.Mei Z, Qiu J, Alcon S, Hashim J, Rotenberg A, Sun Y, et al. Memantine improves outcomes after repetitive traumatic brain injury. Behav Brain Res. 2018; 340:195–204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Luo F, Wu L, Zhang Z, Zhu Z, Liu Z, Guo B, et al. The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models. Br J Pharmacol. 2019; 176:3318–3335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014; 115:157–188. [DOI] [PubMed] [Google Scholar]
- 25.Khan M, Dhammu TS, Matsuda F, Singh AK, Singh I. Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy. BMC Neurosci. 2015; 16:42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Chen HS, Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, et al. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience. 1998; 86:1121–1132. [DOI] [PubMed] [Google Scholar]
- 27.Sinn DI, Lee ST, Chu K, Jung KH, Song EC, Kim JM, et al. Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett. 2007; 411:238–242. [DOI] [PubMed] [Google Scholar]
- 28.Shen LH, Li Y, Chen J, Cui Y, Zhang C, Kapke A, et al. One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke. 2007; 38:2150–2156. [DOI] [PubMed] [Google Scholar]
- 29.Khan M, Sakakima H, Dhammu TS, Shunmugavel A, Im YB, Gilg AG, et al. S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats. J Neuroinflammation. 2011; 8:78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Ding R, Chen Y, Yang S, Deng X, Fu Z, Feng L, et al. Blood-brain barrier disruption induced by hemoglobin in vivo: involvement of up-regulation of nitric oxide synthase and peroxynitrite formation. Brain Res. 2014; 1571:25–38. [DOI] [PubMed] [Google Scholar]
- 31.Yang S, Chen Y, Deng X, Jiang W, Li B, Fu Z, et al. Hemoglobin-induced nitric oxide synthase overexpression and nitric oxide production contribute to blood-brain barrier disruption in the rat. J Mol Neurosci. 2013; 51:352–363. [DOI] [PubMed] [Google Scholar]
- 32.Wada K, Osuka K, Watanabe Y, Usuda N, Fukasawa M, Araki Y, et al. Subarachnoid hemorrhage induces neuronal nitric oxide synthase phosphorylation at Ser1412 in the dentate gyrus of the rat brain. Nitric Oxide. 2018; 81:67–74. [DOI] [PubMed] [Google Scholar]
- 33.Alm P, Sharma HS, Sjöquist PO, Westman J. A new antioxidant compound H-290/51 attenuates nitric oxide synthase and heme oxygenase expression following hyperthermic brain injury. An experimental study using immunohistochemistry in the rat. Amino Acids. 2000; 19:383–394. [DOI] [PubMed] [Google Scholar]
- 34.Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab. 1996; 16:605–611. [DOI] [PubMed] [Google Scholar]
- 35.Sharma HS, Badgaiyan RD, Alm P, Mohanty S, Wiklund L. Neuroprotective effects of nitric oxide synthase inhibitors in spinal cord injury-induced pathophysiology and motor functions: an experimental study in the rat. Ann N Y Acad Sci. 2005; 1053:422–434. [DOI] [PubMed] [Google Scholar]
- 36.Genovese T, Mazzon E, Esposito E, Muià C, Di Paola R, Bramanti P, Cuzzocrea S. Beneficial effects of FeTSPP, a peroxynitrite decomposition catalyst, in a mouse model of spinal cord injury. Free Radic Biol Med. 2007; 43:763–780. [DOI] [PubMed] [Google Scholar]
- 37.Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 2002; 297:1186–1190. [DOI] [PubMed] [Google Scholar]
- 38.Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002; 39:279–291. [DOI] [PubMed] [Google Scholar]
- 39.Sato H, Kita M, Seiki M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem. 1993; 268:23460–23468. [PubMed] [Google Scholar]
- 40.Chiueh CC, Rauhala P. The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications. Free Radic Res. 1999; 31:641–650. [DOI] [PubMed] [Google Scholar]
- 41.Muresanu DF, Sharma A, Patnaik R, Menon PK, Mössler H, Sharma HS. Exacerbation of blood-brain barrier breakdown, edema formation, nitric oxide synthase upregulation and brain pathology after heat stroke in diabetic and hypertensive rats. Potential neuroprotection with cerebrolysin treatment. Int Rev Neurobiol. 2019; 146:83–102. [DOI] [PubMed] [Google Scholar]
- 42.Jiang Z, Li C, Arrick DM, Yang S, Baluna AE, Sun H. Role of nitric oxide synthases in early blood-brain barrier disruption following transient focal cerebral ischemia. PLoS One. 2014; 9:e93134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007; 87:315–424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wang J, Tsirka SE. Contribution of extracellular proteolysis and microglia to intracerebral hemorrhage. Neurocrit Care. 2005; 3:77–85. [DOI] [PubMed] [Google Scholar]
- 45.Parathath SR, Parathath S, Tsirka SE. Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice. J Cell Sci. 2006; 119:339–349. [DOI] [PubMed] [Google Scholar]
- 46.Phares TW, Fabis MJ, Brimer CM, Kean RB, Hooper DC. A peroxynitrite-dependent pathway is responsible for blood-brain barrier permeability changes during a central nervous system inflammatory response: TNF-alpha is neither necessary nor sufficient. J Immunol. 2007; 178:7334–7343. [DOI] [PubMed] [Google Scholar]
- 47.Zhao X, Zhang Y, Strong R, Zhang J, Grotta JC, Aronowski J. Distinct patterns of intracerebral hemorrhage-induced alterations in NF-kappaB subunit, iNOS, and COX-2 expression. J Neurochem. 2007; 101:652–663. [DOI] [PubMed] [Google Scholar]
- 48.Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001; 2:502–511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Wang T, Chen X, Wang Z, Zhang M, Meng H, Gao Y, et al. Poloxamer-188 can attenuate blood-brain barrier damage to exert neuroprotective effect in mice intracerebral hemorrhage model. J Mol Neurosci. 2015; 55:240–250. [DOI] [PubMed] [Google Scholar]
- 50.Wang J, Tsirka SE. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain. 2005; 128:1622–1633. [DOI] [PubMed] [Google Scholar]
- 51.Chen H, Guan B, Chen X, Chen X, Li C, Qiu J, et al. Baicalin attenuates blood-brain barrier disruption and hemorrhagic transformation and improves neurological outcome in ischemic stroke rats with delayed t-PA treatment: involvement of ONOO–MMP-9 pathway. Transl Stroke Res. 2018; 9:515–529. [DOI] [PubMed] [Google Scholar]
- 52.Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. 1994; 265:1883–1885. [DOI] [PubMed] [Google Scholar]
- 53.Gürsoy-Ozdemir Y, Can A, Dalkara T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke. 2004; 35:1449–1453. [DOI] [PubMed] [Google Scholar]
- 54.Wang Z, Zhang S, Xiao Y, Zhang W, Wu S, Qin T, et al. NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev. 2020; 2020:4063562. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Wang H, Chen H, Jin J, Liu Q, Zhong D, Li G. Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion. Life Sci. 2020; 251:117638. [DOI] [PubMed] [Google Scholar]
- 56.Xu F, Shen G, Su Z, He Z, Yuan L. Glibenclamide ameliorates the disrupted blood-brain barrier in experimental intracerebral hemorrhage by inhibiting the activation of NLRP3 inflammasome. Brain Behav. 2019; 9:e01254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Lee ST, Chu K, Jung KH, Kim J, Kim EH, Kim SJ, et al. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab. 2006; 26:536–544. [DOI] [PubMed] [Google Scholar]
- 58.Huang XT, Li C, Peng XP, Guo J, Yue SJ, Liu W, et al. An excessive increase in glutamate contributes to glucose-toxicity in β-cells via activation of pancreatic NMDA receptors in rodent diabetes. Sci Rep. 2017; 7:44120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Ren P, Wu D, Appel R, Zhang L, Zhang C, Luo W, et al. Targeting the NLRP3 inflammasome with inhibitor MCC950 prevents aortic aneurysms and dissections in mice. J Am Heart Assoc. 2020; 9:e014044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Chen B, Wang G, Li W, Liu W, Lin R, Tao J, et al. Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke. Exp Cell Res. 2017; 351:163–172. [DOI] [PubMed] [Google Scholar]
- 61.Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist–a review of preclinical data. Neuropharmacology. 1999; 38:735–767. [DOI] [PubMed] [Google Scholar]
- 62.Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004; 1:101–110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Parcq J, Bertrand T, Montagne A, Baron AF, Macrez R, Billard JM, et al. Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ. 2012; 19:1983–1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.